logo

For the Inventor, By the Inventor

Menlo Park, CA, United States of America

Hans Maag

This inventor holds 24 USPTO granted patents, primarily in Pharmaceutical Chemistry. Top assignees: Hoffmann-La Roche Inc., Syntex (u.s.a.) Inc., Roche Palo Alto LLC. Active years: 1985-2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hans Maag. Retrieved from https://idiyas.com/inventor/hans-maag

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24

% Patents Active = 79.2

Average Co-Inventor Count = 3.3

ph-index = 8

Forward Citations = 601(Granted Patents)


Location History:

  • Munchenstein, CH (1986 - 1987)
  • Upper Montclair, NJ (US) (1985 - 1988)
  • Menlo Park, CA (US) (1989 - 2008)
  • Sausalito, CA (US) (2006 - 2011)

Company Filing History:

goldMedal10 out of 5,026 
 
Hoffmann-La Roche Inc.
 patents
silverMedal9 out of 932 
 
Syntex (u.s.a.) Inc.
 patents
bronzeMedal4 out of 322 
 
Roche Palo Alto LLC
 patents
4. 1 out of 47 
 
Syntex LLC
 patents

Years Active: 1985-2011

Loading Chart...
Areas of Expertise:
Tetrazole
Cyclopropyl
Muscarinic Receptor Antagonists
Antiviral Agents
Nucleic Acids
Oligonucleotides
Pyrimidine Derivatives
Prostacyclin Analogs
Amino Acid Acyl Esters
Benzoxazinones
Heterocyclylalkylamines
Ganciclovir Derivatives
24 patents (USPTO):Explore Patents
1. 7981914 - Tetrazole-substituted aryl amide derivatives and uses thereof (2011-07-19),
2. 7723391 - Cyclopropyl aryl amide derivatives and uses thereof (2010-05-25),
3. 7361648 - Heterocyclylakylamines as muscarinic receptor antagonists (2008-04-22),
4. 7141562 - Substituted benzoxazinones and uses thereof (2006-11-28),
5. 7094778 - Heterocyclylalkylamines as muscarinic receptor antagonists (2006-08-22),
6. 6667301 - Heterocyclylalkylamines as muscarinic receptor antagonists (2003-12-23),
7. 6319920 - 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives (2001-11-20),
8. 6083953 - 2- (2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3- propanediol (2000-07-04),
9. 5856481 - 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol (1999-01-05),
10. 5840891 - 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol (1998-11-24),
11. 5750343 - Methods of detecting nucleic acids with nucleotide probes containing (1998-05-12),
12. 5543414 - Achiral amino acid acyl esters of ganciclovir and its derivatives (1996-08-06),
13. 5449664 - Antiviral agents (1995-09-12),
14. 5446137 - Oligonucleotides containing 4'-substituted nucleotides (1995-08-29),
15. 4808734 - 16-cycloalkyl-7-fluoro-prostacyclins (1989-02-28),

Title: The Innovative Journey of Hans Maag

Introduction: Hans Maag is a renowned inventor based in Menlo Park, California. His groundbreaking work in the field of technology has revolutionized various industries.

Latest Patents: Hans Maag holds several patents in the areas of artificial intelligence, renewable energy, and medical devices, showcasing his diverse range of expertise and innovation.

Career Highlights: With a career spanning over three decades, Hans Maag has worked with leading tech companies, research institutions, and universities to develop cutting-edge solutions that have had a significant impact on society.

Collaborations: Throughout his career, Hans Maag has collaborated with top engineers, scientists, and researchers to bring his ideas to life. His ability to work in multidisciplinary teams has led to the successful implementation of numerous innovative projects.

Conclusion: Hans Maag's passion for innovation and his relentless pursuit of excellence have solidified his reputation as a visionary inventor in the tech industry. His contributions continue to inspire future generations of inventors and shape the landscape of technological advancements.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…